FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to the treatment of comorbid patients with chronic cerebral ischemia and chronic heart failure. The method for treatment involves the administration of 2-ethyl-6-methyl-3-hydroxypyridine succinate to patients receiving basic therapy in the form of a solution for intravenous administration at a dose of 1000 mg intravenously drip once a day for 1 week, then orally at a dose of 250 mg 3 times a day for 12 weeks.
EFFECT: invention allows lengthening the periods of compensation and stabilization in the specified group of patients, is effective and safe.
1 cl, 1 dwg, 6 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTING THE ONE-YEAR RISK OF ADVERSE CARDIOVASCULAR EVENTS IN MEN AFTER DECOMPENSATION OF CHRONIC HEART FAILURE WITH PRESERVED LEFT VENTRICULAR EJECTION FRACTION AND OBSTRUCTIVE SLEEP APNEA SYNDROME | 2021 |
|
RU2767266C1 |
| METHOD FOR PREDICTING THE RISK OF DECOMPENSATED HEART FAILURE AGAINST THE BACKGROUND OF RHEUMATOID ARTHRITIS | 2021 |
|
RU2790190C1 |
| PREPARATION FOR COMPLEX THERAPY OF DISEASES CAUSED BY BETA-CORONAVIRUSES | 2020 |
|
RU2739212C1 |
| METHOD FOR PREDICTATION OF SUPER RESPONSE TO CARDIAC RESYNCHRONIZATION THERAPY FOR PATIENTS WITH CHRONIC HEART FAILURE | 2016 |
|
RU2623487C1 |
| METHOD FOR MULTIVARIATE PREDICTION OF CHRONIC HEART FAILURE AFTER PRIMARY MYOCARDIAL INFARCTION WITH ST SEGMENT ELEVATION DURING 48-WEEK FOLLOW-UP | 2021 |
|
RU2754798C1 |
| METHOD FOR PREDICTION OF RESPONSE TO CARDIAC RESYNCHRONISING THERAPY IN PATIENTS WITH CHRONIC HEART FAILURE | 2018 |
|
RU2716479C1 |
| METHOD FOR DETERMINING ETIOLOGY OF CHRONIC HEART FAILURE | 2020 |
|
RU2748529C1 |
| METHOD FOR PREDICTING PROGRESSION OF ANTHRACYCLINE-INDUCED CHRONIC HEART FAILURE IN PATIENTS WITH BREAST CANCER WITHIN 24 MONTHS | 2022 |
|
RU2793672C1 |
| PHARMACEUTIC COMBINATION OF ETHYLMETHYLHYDROXYPYRIDINE SUCCINATE AND PYRIDOXINE, METHOD OF ITS OBTAINING AND METHOD OF TREATMENT | 2008 |
|
RU2405552C2 |
| METHOD OF TREATING OPEN-ANGLE GLAUCOMA | 2011 |
|
RU2494707C2 |
